诺和诺德预测今年销售额下滑，股价暴跌11%

Core Viewpoint - Novo Nordisk has announced a forecast indicating a decline in sales and profit growth for the year, particularly affecting its U.S. market sales, leading to a significant drop in its stock price [1][5][6]. Group 1: Sales and Profit Forecast - For 2025, Novo Nordisk expects a 10% year-on-year increase in sales and a 6% increase in operating profit, consistent with previous guidance [7]. - The company anticipates a decline in sales for 2026, projecting a decrease of 5% to 13% under constant exchange rates [8]. Group 2: Market Competition and Challenges - The company is facing intense market competition as it seeks to maintain its leading position in the weight loss drug sector [6]. - Novo Nordisk's stock price fell by 46.5% over the past year due to multiple downward revisions of performance guidance, management changes, and increased market competition [2][8]. - The active ingredient in Wegovy and another product, semaglutide, will see its patent expire in 2026 in several markets, adding to the competitive pressure [9]. Group 3: Product Launch and Market Strategy - Novo Nordisk launched the oral version of its weight loss drug Wegovy in the U.S. market in January, which initially showed positive performance [2][8]. - Analysts are closely monitoring the subsequent performance of Wegovy, especially with competitors like Eli Lilly expected to launch their own oral weight loss drug in mid-2026 [2][9]. - There is a strong expectation from investors for Novo Nordisk to leverage its first-mover advantage in direct-to-consumer channels to close the gap with competitors [2][9].